BI 2536 Second Line Monotherapy in SCLC
NCT00412880
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Small Cell
Interventions
DRUG:
BI 2536
Sponsor
Boehringer Ingelheim